Metastatic Disease
'Immense' change prompts new guideline to address salvage therapy for prostate cancer
The American Urological Association released a clinical practice guideline pertaining to salvage therapy for men with prostate cancer.
Virtual reality therapy offers ‘sustained improvement’ in cancer-related pain
Individuals with cancer reported significantly reduced pain immediately following a 10-minute virtual reality (VR) session, study results published in Cancer showed.
‘Paradoxical’ data show routine imaging lacks benefit for head and neck cancer survivors
Compared with expectant management, imaging-based surveillance did not improve outcomes among patients in remission after completion of primary radiation therapy for head and neck cancer, according to data published in JAMA Network Open.
FDA amends gastric cancer indication for Keytruda
The FDA revised an existing indication of pembrolizumab for the first-line treatment of certain patients with gastric or gastroesophageal junction adenocarcinoma.
FDA approves Fruzaqla for treatment of refractory metastatic colorectal cancer
The FDA approved fruquintinib for certain adults with previously treated metastatic colorectal cancer.
FDA expands pediatric solid tumor indication for Rozlytrek, approves new oral formulation
The FDA granted accelerated approval to entrectinib for infants aged 1 month and older who have solid tumors that harbor neurotrophic tyrosine receptor kinase, or NTRK, gene fusion for whom there are no effective treatments.
T-cell receptor therapy ‘definitely effective’ for metastatic solid tumors
More than a third of patients with solid tumors showed evidence of antitumor response after treatment with ADP-A2M4CD8, according to data presented at the virtual ESMO Congress.
Patients with metastatic disease have higher rates of anxiety, depression
SAN DIEGO — Compared with patients who have localized cancer and non-oncologic disease, patients with metastatic disease have higher rates of anxiety and depression, according to a presenter.
Quality of life assessments in oncology trials often don’t — but should — go ‘well beyond treatment’
Most oncology clinical trials that assess quality of life do so only during or shortly after the treatment or intervention rather than continuing after disease progression or until death, according to results of a cross-sectional analysis published in JAMA Network Open.
Few patients enroll in cancer clinical trials as first line of treatment
An “exceedingly low” percentage of patients with cancer enroll in clinical trials as the first course of therapy, according to results of a study conducted at Penn State College of Medicine and published in Journal of the National Comprehensive Cancer Network.